Literature DB >> 23359769

Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer.

Chan-Zhen Liu1, Li Zhang, Xiao-Hong Chang, Ye-Xia Cheng, Hong-Yan Cheng, Xue Ye, Tian-Yun Fu, Jun Chen, Heng Cui.   

Abstract

OBJECTIVE: Transforming growth factor-1 (TGF-β1), vascular endothelial growth factor (VEGF), and interleukin-10 (IL-10) may be critical cytokines in the microenvironment of a tumor, playing roles in immune suppression. This study was conducted to elucidate the roles and immunosuppressive functions of these cytokines in epithelial ovarian cancer (EOC).
METHODS: The expression levels of TGF-β1, VEGF and IL-10 in malignant tissue were evaluated by immune- histochemistry and compared with corresponding borderline, benign, and tumor-free tissues. Moreover, relationships among the levels of these cytokines and correlations between expression and the prognosis of EOC were analyzed by Pearson rank correlations and multi-factor Logistic regression. The roles of TGF-β1, VEGF, and IL-10 in the immunosuppressive microenvironment of ovarian cancer were studied through dendritic cell (DC) maturation and CD4+CD25+FoxP3+ Treg generation in vitro experiments.
RESULTS: TGF-β1, VEGF, and IL-10 were expressed in 100%, 74.69%, and 54.96% of EOC patients, respectively. TGF-β1 was an independent prognostic factor for EOC. IL-10 was significantly co-expressed with VEGF. In vitro, VEGF and TGF-β1 strongly interfered with DC maturation and consequently led to immature DCs, which secreted high levels of IL-10 that accumulated around the tumor site. TGF-β1 and IL-10 induced Treg generation without antigen presentation in DCs.
CONCLUSIONS: TGF-β1, VEGF and IL-10 play important roles in EOC and can lead to frequent immune evasion events.

Entities:  

Keywords:  Cytokines; Epithelial ovarian cancer; Immunosuppression; Tumor microenvironment

Year:  2012        PMID: 23359769      PMCID: PMC3555263          DOI: 10.1007/s11670-012-0130-y

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  41 in total

Review 1.  TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights.

Authors:  H L Moses; E Y Yang; J A Pietenpol
Journal:  Cell       Date:  1990-10-19       Impact factor: 41.582

2.  The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

Authors:  Dominik Wolf; Anna M Wolf; Holger Rumpold; Heidi Fiegl; Alain G Zeimet; Elisabeth Muller-Holzner; Martina Deibl; Guenther Gastl; Eberhard Gunsilius; Christian Marth
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

3.  Characterisation of dendritic cell subsets in lung cancer micro-environments.

Authors:  A Bergeron; F El-Hage; M Kambouchner; D Lecossier; A Tazi
Journal:  Eur Respir J       Date:  2006-08-09       Impact factor: 16.671

Review 4.  Transforming growth factor-beta: recent advances on its role in immune tolerance.

Authors:  Martin A Kriegel; Ming O Li; Shomyseh Sanjabi; Yisong Y Wan; Richard A Flavell
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

5.  Human ovarian carcinoma cells generate CD4(+)CD25(+) regulatory T cells from peripheral CD4(+)CD25(-) T cells through secreting TGF-beta.

Authors:  Xiao Li; Feng Ye; Huaizeng Chen; Weiguo Lu; Xiaoyun Wan; Xing Xie
Journal:  Cancer Lett       Date:  2007-03-13       Impact factor: 8.679

6.  Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer.

Authors:  Sebastian Hinz; Laia Pagerols-Raluy; Hans-Heinrich Oberg; Ole Ammerpohl; Sandra Grüssel; Bence Sipos; Robert Grützmann; Christian Pilarsky; Hendrik Ungefroren; Hans-Detlev Saeger; Günter Klöppel; Dieter Kabelitz; Holger Kalthoff
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

7.  A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease.

Authors:  Peter Brinkrolf; Silke Landmeier; Bianca Altvater; Christiane Chen; Sibylle Pscherer; Annegret Rosemann; Andreas Ranft; Uta Dirksen; Heribert Juergens; Claudia Rossig
Journal:  Int J Cancer       Date:  2009-08-15       Impact factor: 7.396

Review 8.  Transforming growth factor-beta regulation of immune responses.

Authors:  Ming O Li; Yisong Y Wan; Shomyseh Sanjabi; Anna-Karin L Robertson; Richard A Flavell
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

9.  FOXP3 defines regulatory T cells in human tumor and autoimmune disease.

Authors:  Ilona Kryczek; Rebecca Liu; Guobin Wang; Ke Wu; Xiaogong Shu; Wojciech Szeliga; Linhua Vatan; Emily Finlayson; Emina Huang; Diane Simeone; Bruce Redman; Theodore H Welling; Alfred Chang; Weiping Zou
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

10.  Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer.

Authors:  Sung Yong Oh; Hyuk-Chan Kwon; Sung-Hyun Kim; Jin Seok Jang; Min Chan Kim; Kyeong Hee Kim; Jin-Yeong Han; Chung Ock Kim; Su-Jin Kim; Jin-sook Jeong; Hyo-Jin Kim
Journal:  BMC Cancer       Date:  2008-05-01       Impact factor: 4.430

View more
  18 in total

1.  API5 confers tumoral immune escape through FGF2-dependent cell survival pathway.

Authors:  Kyung Hee Noh; Seok-Ho Kim; Jin Hee Kim; Kwon-Ho Song; Young-Ho Lee; Tae Heung Kang; Hee Dong Han; Anil K Sood; Joanne Ng; Kwanghee Kim; Chung Hee Sonn; Vinay Kumar; Cassian Yee; Kyung-Mi Lee; Tae Woo Kim
Journal:  Cancer Res       Date:  2014-04-25       Impact factor: 12.701

Review 2.  Platelet effects on ovarian cancer.

Authors:  Ashley N Davis; Vahid Afshar-Kharghan; Anil K Sood
Journal:  Semin Oncol       Date:  2014-04-23       Impact factor: 4.929

Review 3.  The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies.

Authors:  Haoqing Shi; Xiangjie Qi; Bin Ma; Yanwei Cao; Lina Wang; Lijiang Sun; Haitao Niu
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

4.  Clinical significance of serum transforming growth factor-beta 1 (TGF-β1) levels in patients with epithelial ovarian cancer.

Authors:  Faruk Tas; Senem Karabulut; Murat Serilmez; Rumeysa Ciftci; Derya Duranyildiz
Journal:  Tumour Biol       Date:  2013-12-06

5.  The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.

Authors:  David M Woods; Karrune Woan; Fengdong Cheng; Hongwei Wang; Patricio Perez-Villarroel; Calvin Lee; Maritza Lienlaf; Peter Atadja; Edward Seto; Jeffrey Weber; Eduardo M Sotomayor; Alejandro Villagra
Journal:  Melanoma Res       Date:  2013-10       Impact factor: 3.599

6.  Anti-CD40 antibody and toll-like receptor 3 ligand restore dendritic cell-mediated anti-tumor immunity suppressed by morphine.

Authors:  Ming-Cheng Chang; Yu-Li Chen; Ying-Cheng Chiang; Ya-Jung Cheng; Yu-Wei Jen; Chi-An Chen; Wen-Fang Cheng; Wei-Zen Sun
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

Review 7.  IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.

Authors:  Ramesh B Batchu; Oksana V Gruzdyn; Bala K Kolli; Rajesh Dachepalli; Prem S Umar; Sameer K Rai; Namrata Singh; Pavan S Tavva; Donald W Weaver; Scott A Gruber
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Cytokines as Prognostic Biomarkers of Epithelial Ovarian Cancer (EOC): A Systematic Review and Meta-Analysis.

Authors:  Moh Nailul Fahmi; Heru Pradjatmo; Indwiani Astuti; Ricvan Dana Nindrea
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

Review 9.  Tumor and Systemic Immunomodulatory Effects of MEK Inhibition.

Authors:  Lauren Dennison; Aditya A Mohan; Mark Yarchoan
Journal:  Curr Oncol Rep       Date:  2021-02-06       Impact factor: 5.945

10.  M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients.

Authors:  Grażyna Ewa Będkowska; Sławomir Ławicki; Ewa Gacuta; Przemysław Pawłowski; Maciej Szmitkowski
Journal:  J Ovarian Res       Date:  2015-05-03       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.